The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index; 1 of the 16 sources its claims cite were checked for support.
Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life -- a double-blind, placebo-controlled study: Randomised clinical trial: B. bifidum MIMBb75 in IBS
Open accessAbstract
BACKGROUND: Recent research suggests that an imbalance of the intestinal microbiota and a dysfunctional intestinal barrier might trigger irritable bowel syndrome (IBS). As probiotics have been reported to restore the intestinal microbiota and the gut barrier, the therapeutic potential of probiotics within IBS became of strong interest. AIM: To assess the efficacy of Bifidobacterium bifidum MIMBb75 in IBS. METHODS: A total of 122 patients were randomised to receive either placebo (N=62) or MIMBb75 (N=60) once a day for 4 weeks. The severity of IBS symptoms was recorded daily on a 7-point Likert scale. RESULTS: MIMBb75 significantly reduced the global assessment of IBS symptoms by -0.88 points (95% CI: -1.07; -0.69) when compared with only -0.16 (95% CI: -0.32; 0.00) points in the placebo group (P<0.0001). MIMBb75 also significantly improved the IBS symptoms pain/discomfort, distension/bloating, urgency and digestive disorder. The evaluation of the SF12 sum scores showed a significant gain in quality of life within the bifidobacteria group. Furthermore, adequate relief was reported by 47% of the patients in the bifidobacteria and only by 11% of the patients in the placebo group (P<0.0001). Overall responder rates were 57% in the bifidobacteria group but only 21% in the placebo group (P=0.0001). MIMBb75 was well tolerated and adverse events were not different from placebo. CONCLUSIONS: Bifidobacterium bifidum MIMBb75 effectively alleviates global IBS and improves IBS symptoms simultaneously with an improvement of quality of life. Considering the high efficacy of MIMBb75 in IBS along with the good side-effect profile, MIMBb75 is a promising candidate for IBS therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
17 Own result · 12 Not checked yet · 9 Own method · 6 Own interpretation · 1 Partly supported · 1 No basis given · accuracy not yet measured
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The study population has mild to moderate IBS symptoms as evidenced by the indicated SGA-baseline values.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > DISCUSSION AND CONCLUSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The reduction persisted during wash-out phase (2.33 in the bifidobacteria group vs. 3.47 in the placebo group, P < 0.0001).”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Secondary endpoints
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and distension ⁄ bloating by )0.92 points (95% CI: )1.15; )0.69) vs. )0.21(95% CI: )0.37; )0.05) in the placebo group (P < 0.0001) during the treatment.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Secondary endpoints
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The evaluation of the SGA on a weekly basis showed a significant benefit for patients within the bifidobacteria group for every single week starting the second week of treatment till the end of the study (Figure 3).”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Bifidobacterium bifidum
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Additionally, no severe adverse events have been recorded in either group.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Adverse events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“First of all, the study population was not large enough for a subgroup analysis of IBS subtypes.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > DISCUSSION AND CONCLUSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The allocation was blinded to both patients and site staff.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Study design
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The ability of specific strains to adhere well to intestinal cells may play a pivotal role in altering the intestinal microbiota and increasing the intestinal barrier, which might be of significant value especially in the treatment of IBS.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > INTRODUCTION
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, B. bifidum MIMBb75 also significantly improved the quality of life.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > DISCUSSION AND CONCLUSION
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“While some studies might have missed to show efficacy due to small sample size and randomisation errors, several different probiotic strains did repeatedly show no significant improvement in IBS.[20][21][22][23][24]”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > DISCUSSION AND CONCLUSION
What the sources say
- Not checked yetcites [20][21][22][23][24]
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 28
- The quote only partly states this claim. 2
- Probably not a substantial claim. 11
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“As probiotics have been reported in several studies to restore the intestinal microbiota and gut barrier as well as hinder bacterial translocation, the therapeutic potential of probiotics in IBS has become of strong interest.10,11”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > INTRODUCTION
What the sources say
- Partly supportedcites [10] Alvares-Olmos, 2001, Probiotic agents and infectious diseases: a modern perspective on a traditional therapy, Clin Infect Dis sourceExperimental — accuracy not yet measured
The Abstract says probiotics can improve the balance of gut flora, and Mechanisms of Action describes their inhibition of pathogen attachment. The copy does not report that probiotics restore the gut barrier or hinder bacterial translocation; the translocation mention in Safety, Advantages, and Disadvantages concerns a risk factor for infection, not a probiotic benefit. (LLM, conf=0.86)
- Not checked yetcites [11] Salminen, 1996, Clinical uses of probiotics for stabilizing the gut mucosal barrier: successful strains and future challenges, Antonie Van Leeuwenhoek source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Bowel movement satisfaction (digestive disorder) decreased from 3.89 to 2.44 in the bifidobacteria group vs. 3.69 to 3.47 in the placebo group (P = 0.0002) after treatment.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Secondary endpoints
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall responder rates were 57% in the bifidobacteria group and only 21% in the placebo group (P = 0.0001).”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Treatment responders
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At the end of treatment, 43% of the patients in the bifidobacteria group achieved adequate relief compared with only 8% in the placebo group (P < 0.0001).”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Global efficacy at physician site
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Only 36 adverse events were reported with suspected relation to the study product, 13 in the placebo and 23 in the treatment group, but no significant differences could be detected in the side-effects profile of B. bifidum MIM-Bb75 vs. placebo”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Adverse events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Urgency was significantly reduced by )0.67 points (95% CI: )0.86; )0.48) vs. )0.21(95% CI: )0.35; )0.07) in the placebo group (P = 0.0001) during the treatment but not during the wash-out phase.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Secondary endpoints
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“MIMBb75 significantly reduced the global assessment of IBS symptoms by )0.88 points (95% CI: )1.07; )0.69) when compared with only )0.16 (95% CI: )0.32; 0.00) points in the placebo group (P < 0.0001).”
- Also stated in: § Bifidobacterium bifidum · plain
“MIMBb75 significantly improved global IBS symptoms by )0.88 points (95% CI: )1.07; )0.69) (from 2.95 in the run in phase to 2.07 in the treatment phase) compared with only )0.16 points (95% CI: )0.32; 0.00) (from 2.79 in the run in phase to 2.63 in the treatment phase) in the placebo group (P < 0.0001) using the 7-point Likert scale.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Abstract
plaindirectn = 122 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § Bifidobacterium bifidum · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Bifidobacterium bifidum MIMBb75 showed a significant reduction of pain ⁄ discomfort by )0.82 points (95% CI: )1.01; )0.63) vs. )0.18(95% CI: )0.35; )0.01) in the placebo group (P < 0.0001)”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Secondary endpoints
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No effects could be detected for frequency of bowel movement and feeling of incomplete bowel evacuation (Figure 4).”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Secondary endpoints
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The difference between the treatment arms was only a little bit less pronounced when considering only the symptom 'pain ⁄ discomfort' where responder rates were calculated to be 48% in the bifidobacteria and only 24% in the placebo group (P = 0.008)”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Treatment responders
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Physical health sum significantly changed by 3.99 in the bifidobacteria group and by only 1.08 in the placebo group compared with baseline (P = 0.0185).”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Health-related quality of life
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Mental health sum significantly changed by 5.78 in the bifidobacteria group and by only 1.58 in the placebo group compared with baseline (P = 0.0083).”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Health-related quality of life
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The reduction persisted during the wash-out phase.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Secondary endpoints
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one. The quote only partly states this claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 132 patients were included into the study and 122 patients were successfully randomised to receive either placebo (N = 62) or B. bifidum MIMBb75 (N = 60).All randomised patients were analysed for intent to treat (N = 122).”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Subjects
plainn = 122- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The primary analysis was based on the intent-to-treat population where all successfully randomised patients were included.Missing post-baseline values were imputed by the baseline value for the primary target criterion and these patients were evaluated as nonresponders”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Statistical analysis
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The prospectively defined primary efficacy variable was the subject's global assessment of IBS symptoms using a 7-point Likert scale.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Endpoint definitions
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The treatment was allocated according to a computer-generated blocked randomisation list with a block size of 4.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Study design
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“This study was performed as a prospective, multi-centre, randomised, double-blind, placebo-controlled, two-arm nutritional study.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Study design
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
In the paper
“Based on published data, 17 a difference of 0.6 points in the SGA of IBS symptoms between B. bifidum MIMBb75 and placebo on the 7-point Likert scale was anticipated”
- Also stated in: § Sample size estimation. · plain
“With these assumptions, a Wilcoxon-Mann-Whitney test with a two-sided significance level of a = 0.05 and a power of 1)b = 0.8, a sample size of 47 patients per group was required.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Sample size estimation.
What the sources say
- Not checked yetcites [17] Whorwell, 2006, Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome, Am J Gastroenterol source
plainn = 132- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
- Also stated in: § Sample size estimation. · plain
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The block size was not disclosed to the investigators.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Study design
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“In terms of baseline characteristics, there were no significant differences between the groups”
- Also stated in: § Baseline characteristics · boosted
“Demographics were well balanced between the treatment groups”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Baseline characteristics
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one. The quote only partly states this claim.
- Also stated in: § Baseline characteristics · boosted
None of the sources cited for this claim have been checked yet.
In the paper
“Several studies have observed altered intestinal microbiota with a significant lack of bifidobacteria 25,26 and a dysfunctional intestinal barrier in IBS patients.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > DISCUSSION AND CONCLUSION
What the sources say
- Not checked yetcites [25] Kerckhoffs, 2009, Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients, World J Gastroenterol source
- Not checked yetcites [26] Si, 2004, Intestinal microecology and quality of life in irritable bowel syndrome patients, World J Gastroenterol source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Guglielmetti et al. showed that BopA, a surface protein, is directly involved in the adhesion to Caco-2 cells.15”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Probiotic preparation
What the sources say
- Not checked yetcites [15] Guglielmetti, 2008, Implication of an outer surface lipoprotein in adhesion of bifidobacterium bifidum to caco-2 cells, Appl Environ Microbiol source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“BopA has been found in several strong adhesive B. bifidum strains, indicating that BopA might be an indicator of strong adherence.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Probiotic preparation
What the sources say
- Not checked yetcites [15] Guglielmetti, 2008, Implication of an outer surface lipoprotein in adhesion of bifidobacterium bifidum to caco-2 cells, Appl Environ Microbiol source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“A total of 16 RCTs were included in the analysis.Of those, exclusively one Bifidobacterium strain showed efficacy for the improvement of IBS symptoms in two appropriately designed studies.4”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > DISCUSSION AND CONCLUSION
What the sources say
- Not checked yetcites [4] Brenner, 2009, The utility of probiotics in the treatmet of irritable bowel syndrome: a systematic review, Am J Gastroenterol source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Considering the high efficacy of MIMBb75 in IBS along with the good side-effect profile, MIMBb75 is a promising candidate for IBS therapy.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: Conventional medical treatment for IBS is unsatisfactory.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this study, B. bifidum MIMBb75 significantly improved global IBS as well as its related symptoms such as pain ⁄ discomfort, distension ⁄ bloating and digestive disorders compared with placebo.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > DISCUSSION AND CONCLUSION
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Recent research suggests that an imbalance of the intestinal microbiota with a significant reduction of bifidobacteria and a dysfunctional intestinal barrier with subsequent bacterial translocation may contribute to the development of IBS and its symptoms.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > INTRODUCTION
What the sources say
- Not checked yetcites [5][6]][7][8][9]
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Additionally B. bifidum MIMBb75 showed considerably more adhesion to the Caco-2 monolayer in the presence of fucose and mannose and less when B. bifidum MIMBb75 grew in Oxgall bile salts compared with standard environmental conditions.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Probiotic preparation
What the sources say
- Not checked yetcites [16] Guglielmetti, 2009, Study of the adhesion of bifidobacterium bifidum MIMBb75 to human intestinal cell lines, Curr Microbiol source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“However, the efficacy of probiotics is strongly strain specific and only certain strains might be able to improve IBS and its symptoms.[12][13][14]”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > INTRODUCTION
What the sources say
- Not checked yetcites [12][13][14]
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Additionally, gut mucosal barrier disruption has been proven to be associated with bacterial translocation and inflammatory conditions.[4][5][6]”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > DISCUSSION AND CONCLUSION
What the sources say
- Not checked yetcites [4][5][6]
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Bifidobacterium bifidum MIMBb75 effectively alleviates global IBS and improves IBS symptoms simultaneously with an improvement of quality of life.”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Abstract
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: Conventional medical treatment for IBS is unsatisfactory.
In the paper
“The colonisation strategy of this bacterium could be influenced by several factors varying along the gastrointestinal tract, such as the presence of specific sugars and bile salts and the pH, likely supporting adhesion of B. bifidum MIMBb75 to distal sites of the gut.16”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > Probiotic preparation
What the sources say
- Not checked yetcites [16] Guglielmetti, 2009, Study of the adhesion of bifidobacterium bifidum MIMBb75 to human intestinal cell lines, Curr Microbiol source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“It has been stated that the imbalance of the microbiotic composition may lead to a different fermentation pattern, especially with increased hydrogen production resulting in bloating.28,29”
§ Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life --a double-blind, placebo-controlled study > DISCUSSION AND CONCLUSION
What the sources say
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper relies on this without support.
Conventional medical treatment for IBS is unsatisfactory.
“As the conventional medical treatment of IBS is unsatisfactory, we have evaluated the efficacy of B. bifidum MIMBb75 in IBS in a double blind, placebo-controlled multi-centre study.”
The paper relies on this without support.
No probiotic strain has yet been shown to significantly alleviate IBS while also improving quality of life.
“Additionally, to our knowledge, no probiotic strain could show to significantly alleviate irritable bowel syndrome and simultaneously improve the quality of life.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The second study did not detect any effects of the specific probiotic treatment on the frequency of bowel movements and feelings of incomplete evacuation.56”
From Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice - an evidence-based international guide (2013) · cites this paper as [56]
In the citing paper
“For example, one study reported that Bifidobacterium bifidum MIMBb75 was beneficial for improving global IBS symptoms, bloating and aspects of health-related quality of life (physical and mental health), but not for frequency of bowel movement and feeling of incomplete bowel evacuation.56”
From Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice - an evidence-based international guide (2013) · cites this paper as [56]
In the citing paper
“In some of the better quality trials bifidobacteria, such as Bifidobacterium infantis 35624,215 224 241 Bifidobacterium lactis DN 173010208 225 and Bifidobacterium bifidum MIMBb75,226 seem to be advantageous and in others probiotic mixtures appear to be useful.214 229 233”
From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [226]
In the citing paper
“Other smaller studies reported some beneficial effects with other probiotic strains including Bifidobacterium animalis DN-173 010 (74), Bifidobacterium bifidum MIMBb75 (72), Lactobacillus plantarum 299V (117), Saccharomyces boulardii (37), and combination of Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 (144) and multispecies probiotic mixtures (71, 87, 88).”
From Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome (2013) · cites this paper as [72]
In the citing paper
“Specific probiotics help reduce bloating/distension in some patients with IBS Moderate [147,149-150,155-156,168-170, 174-177,179-183]”
From Gut microbiota role in irritable bowel syndrome: New therapeutic strategies (2016) · cites this paper as [155]
In the citing paper
“With specific probiotics, improvement of symptoms has been shown to lead to improvement in some aspects of health-related quality of life Moderate [147,150,152,155,169-170,174,176-177,179-180,183-184,186]”
From Gut microbiota role in irritable bowel syndrome: New therapeutic strategies (2016) · cites this paper as [155]
In the citing paper
“Specific probiotics may help reduce constipation in some patients with IBS Low [155-156,183,185]”
From Gut microbiota role in irritable bowel syndrome: New therapeutic strategies (2016) · cites this paper as [155]
Citations
Cites
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
O’Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O’Sullivan, G. C., Kiely, B., Collins, J. K., Shanahan, F., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.050 · Cited by 1,448
Kassinen, A., Krogius-Kurikka, L., Mäkivuokko, H., Rinttilä, T., Paulin, L., Corander, J., Malinen, E., Apajalahti, J., & Palva, A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.005 · Cited by 1,002
Whorwell, P. J., Altringer, L., Morel, J., Bond, Y., Charbonneau, D., O'Mahony, L., Kiely, B., Shanahan, F., & Quigley, E. M. M. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00734.x · Cited by 799
Eradication of Small Intestinal Bacterial Overgrowth Reduces Symptoms of Irritable Bowel Syndrome
Pimentel, M., Chow, E. J., & Lin, H. C. (2000) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.03368.x · Cited by 780
Pimentel, M., Chow, E. J., & Lin, H. C. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07234.x · Cited by 670
SILK, D. B. A., DAVIS, A., VULEVIC, J., TZORTZIS, G., & GIBSON, G. R. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03911.x · Cited by 551
Salminen, S., Isolauri, E., & Salminen, E. (1996) · Antonie van Leeuwenhoek · doi:10.1007/bf00395941 · Cited by 406
Kim, H. J., Vazquez Roque, M. I., Camilleri, M., Stephens, D., Burton, D. D., Baxter, K., Thomforde, G., & Zinsmeister, A. R. (2005) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2005.00695.x · Cited by 400
GUYONNET, D., CHASSANY, O., DUCROTTE, P., PICARD, C., MOURET, M., MERCIER, C. ‐., & MATUCHANSKY, C. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03362.x · Cited by 365
Cited by
Sorted by citations
Items 201–287 of 287
Prebiotics, Probiotics, and Synbiotics: A Bifidobacterial View
Morelli, L., Callegari, M. L., & Patrone, V. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805060-6.00017-x · Cited by 6
Bu, F.-L., Chen, R., Lin, Z., Cao, H., Robinson, N., Liang, N., & Liu, J. (2020) · European Journal of Integrative Medicine · doi:10.1016/j.eujim.2020.101177 · Cited by 5
Manandhar, A., Sabir, G., Abdelhady, H. A., Abakar, A. O., Gangavarapu, R. R., Mahmud, S. A., & Malasevskaia, I. A. (2024) · Cureus · doi:10.7759/cureus.72089 · Cited by 4
Probiotics and prebiotics, including fibers and medicinal foods
Jana, T., Acker, B. W., & Cash, B. D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813037-7.00042-x · Cited by 4
Zhao, X., Shi, L., Ning, B., Zhao, Z., Li, X., Zhu, M., Zhang, Y., & Fu, J. Q. (2023) · Immunity Inflammation and Disease · doi:10.1002/iid3.857 · Cited by 4
Quigley, E. M. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804024-9.00014-8 · Cited by 4
Владимирович, И. К., Grechishnikova, V. R., Reshetova, M. S., & Ivashkin, V. T. (2021) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2021-31-1-54-63 · Cited by 4
Laterza, L., Napoli, M., Petito, V., Scaldaferri, F., Gaetani, E., & Gasbarrini, A. (2022) · Minerva Medica · doi:10.23736/s0026-4806.21.07015-4 · Cited by 3
Effectiveness Of Probiotics In Irritable Bowel Syndrome: A Systematic Review With Meta-Analysis
Nikfar, S., Mozafari, S., Didari, T., & Abdollahi, M. R. (2014) · Value in Health · doi:10.1016/j.jval.2014.08.799 · Cited by 3
Bacterial therapy for irritable bowel syndrome
Talley, N. J., Irani, M. Z., & Keely, S. (2020) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(20)30079-0 · Cited by 3
Postbiotics: Potential as functional ingredients—A review
Sarkar, S. (2024) · Food Nutrition Chemistry · doi:10.18686/fnc241 · Cited by 2
Pathan, S., Karlegan, V., & Shih, D. Q. (2026) · Fermentation · doi:10.3390/fermentation12020075 · Cited by 2
Reizdarmsyndrom – neue Leitlinie und Stellenwert von Probiotika
Krammer, H., Schmidt-Lauber, M., & Krammer, J. (2023) · coloproctology · doi:10.1007/s00053-023-00726-0 · Cited by 2
Bifidobacterium bifidum SAM-VI Riboswitch Conformation Change Requires Peripheral Helix Formation
Xiao, W., Liu, G., Chen, T., Zhang, Y., & Lu, C. (2024) · Biomolecules · doi:10.3390/biom14070742 · Cited by 2
Coriat, J., Azuero, A. J., Gil-Tamayo, S., Rueda, M. C., Cardona, C. C., & Rosselli, D. (2017) · Revista Colombiana de Gastroenterología · doi:10.22516/25007440.141 · Cited by 2
New drugs (enzymes and probiotics) in clinical practice
Minushkin, O. N. (2022) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2022-16-15-98-103 · Cited by 2
Masset, Z., Gunaratnam, S., Millette, M., McFarland, L. V., & Lacroix, M. (2024) · Antibiotics · doi:10.3390/antibiotics13040365 · Cited by 2
Fukuhara, S., Ohmori, H., Matsumoto, T., Takei, D., MATSUOKA, K., Takemoto, M., SUMIMOTO, R., & Ohdan, H. (2024) · Bioscience of Microbiota Food and Health · doi:10.12938/bmfh.2024-048 · Cited by 2
Endocrine gastroenterological aspects of metabolic dysfunction
Chernyadyeva, T. I., Bontsevich, R. A., & Gaus, O. V. (2025) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-229-9-36-43 · Cited by 2
Lactic Acid Bacteria and Gut Health
Li, H., & Fang, Z. (2019) · Springer eBooks · doi:10.1007/978-981-13-7832-4_8 · Cited by 2
Diet in irritable bowel syndrome
Sienkiewicz, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821324-7.00013-7 · Cited by 2
SCFAs in T1D: A microbiota-targeted approach for immune tolerance
Mariño, E. (2022) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2022.100355 · Cited by 2
Experimental therapies in Irritable Bowel Syndrome
Włodarczyk, J., Szałwińska, P., Waśniewska, A., & Fichna, J. (2023) · Folia Medica Cracoviensia · doi:10.24425/fmc.2021.137209 · Cited by 2
Translation of Immunomodulatory Effects of Probiotics into Clinical Practice
Ryan, J. C., Narasimha, S. V., Pattison, R., Zackria, R., Ghobrial, Y., Basit, S. A., Ammar, T. A. R. A., Jayaraman, V., Stone, C. D., & Shih, D. Q. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.109864 · Cited by 2
Bifidobacteria spp. As a Potential Probiotic for the Treatment of Various Diseases
Eya, C. P., Eya, I. E., & Ebhodaghe, F. E. (2024) · Journal of applied science and environmental management · doi:10.4314/jasem.v28i5.31 · Cited by 3
The Impact of Yoyo Dieting and Resistant Starch on Weight Loss and Gut Microbiome in C57Bl/6 Mice
Phuong-Nguyen, K., O’Hely, M., Kowalski, G. M., McGee, S. L., Aston‐Mourney, K., Connor, T., Mahmood, M. Q., & Rivera, L. R. (2024) · Nutrients · doi:10.3390/nu16183138 · Cited by 4
Probiotic Properties of Bifidobacteria Isolated from Feces of Infants
Kang, C.-H., Kim, Y., Han, S. H., Jeong, Y., Park, H. M., & Paek, N.-S. (2019) · Journal of Dairy Science and Biotechnology · doi:10.22424/jmsb.2019.37.1.40 · Cited by 2
Does VSL#3 Really Improve Symptoms in Children With IBS?
Shulman, R. J., & Smith, E. O. (2011) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e31823df69b · Cited by 2
An Overview of Probiotic Research
Ζουμποπούλου, Γ., Tsakalidou, E., & Thomas, L. V. (2017) · Wiley eBooks · doi:10.1002/9781119214137.ch8 · Cited by 3
Paraprobiotics for irritable bowel syndrome: all that glitters is not gold
Enck, P., Schemann, M., & Frieling, T. (2020) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(20)30243-0 · Cited by 2
Tripathy, S., Patel, A. R., Verma, D. K., Sıngh, S., Utama, G. L., Thakur, M., Niamah, A. K., Shah, N., Al‐Sahlany, S. T. G., Srivastav, P. P., et al. (2023) · Wiley eBooks · doi:10.1002/9781119874096.ch21 · Cited by 2
Bifidobacterium bifidum MIMBb75 in irritable bowel syndrome: authors’ reply
Guglielmetti, S., Mora, D., Gschwender, M., & Popp, K. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04691.x · Cited by 1
Self-citationOtaru, N., Pugin, B., Plüss, S., Hojsak, I., Braegger, C., & Lacroix, C. (2024) · Microbiome Research Reports · doi:10.20517/mrr.2023.75 · Cited by 1
Gang, H., Wei, J., McFarland, L. V., Zahra, R., Saez, M. E., Blanco-Rojo, R., & Millette, M. (2025) · Beneficial Microbes · doi:10.1163/18762891-bja00084 · Cited by 1
Sen, D., Datta, S., Biswas, S., Samadder, A., & Nandi, S. (2025) · Current Cancer Drug Targets · doi:10.2174/0115680096373099250709100217 · Cited by 1
Naz, S. S., & Ortega, J. S. (2025) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-025-10745-6 · Cited by 1
Viable and Heat-Inactivated Bifidobacterium bifidum MIMBb75 Protect the Intestinal Barrier
Storr, M., & Gschwender, M. (2026) · Microorganisms · doi:10.3390/microorganisms14061349 · Cited by 1
Self-citationAhmadi, M., Shahbahrami, R., Khajeh, F., Marand, M. J., Bazzaz, S., Mofid, V., & Hosseini, S. M. (2026) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2026.105932 · Cited by 1
Biotic therapies for irritable bowel syndrome: current interventions
Wodarczyk, G., Winte, M. F., Mastellone, D., Singh, T., DeSipio, J., & Phadtare, S. (2026) · Gastroenterology report · doi:10.1093/gastro/goag062 · Cited by 1
Postbiotics: An Overview and Recommendations for Improved Reporting
Anjum, M., & Ouwehand, A. C. (2026) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.70554 · Cited by 1
Deep Exploration of Bifidobacteria through Metabolomics Study
Li, J., Jiang, Y., Shen, Y., Li, Q., & Sun, Z. (2018) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2018.65008 · Cited by 1
Takahashi, J., & Rindfleisch, J. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35868-2.00105-5 · Cited by 2
Clinical Significance of Bifidobacteria
Riedel, C. U. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-805060-6.00013-2 · Cited by 3
Irritable bowel syndrome dietary management
Staudacher, H. M., & Parkes, G. C. (2014) · Wiley eBooks · doi:10.1002/9781118872796.ch3.19 · Cited by 1
Bifidobacterium bifidum MIMBb75 in irritable bowel syndrome
Quigley, E. M. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04671.x · Cited by 1
Paraprobiotics for irritable bowel syndrome: all that glitters is not gold – Authors' reply
Andresen, V., Gschossmann, J. M., & Layer, P. (2020) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(20)30239-9 · Cited by 1
The role of hydrogenotrophic microbiota in the human gut
Wang, T. (2022) · doi:10.18174/569022 · Cited by 1
Food‐related Symptoms of Irritable Bowel Syndrome
Dapoigny, M. C. (2013) · Wiley eBooks · doi:10.1002/9781118444689.ch8
Probiotics, with special emphasis on their role in the management of irritable bowel syndrome
Stevenson, C., & Blaauw, R. (2012) · Pharmacy management
Diet Therapy in Irritable Bowel Syndrome; A review
Beheshti, S., Hashemian, M., Mohammadi‐Nasrabadi, F., Hekmatdoost, A., Poustchi, H., & Malekzadeh, R. (2014) · GOVARESH
Gastrointestinal Diseases During Pregnancy
Akbari, M., & Wolf, J. L. (2017) · Springer eBooks · doi:10.1007/978-3-319-39328-5_1
Villa, C. (2012) · TSpace (University of Toronto)
Varankovich, N. V. (2017) · University Library - University of Saskatchewan (University of Saskatchewan)
Wen, B. (2015) · TSpace (University of Toronto)
Nakov, V., & Nakov, R. (2018) · International Journal of Advanced Research · doi:10.21474/ijar01/7122
Gut microbiata: underestimated or exaggerated?
Karakan, T. (2018) · Mucosa · doi:10.33204/mucosa.476149
Nutritional Therapies for Irritable Bowel Syndrome: a Focus on Prebiotics and Probiotics
Zoll, B. E., & Ahuja, N. K. (2020) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-020-00320-z · Cited by 1
Molecular Detection of Age-Related Abundance and Diversity of Bifidobacterium spp. in Pastured Goats
Ndegwa, E. N., & Agyemang, A. (2022) · Journal of Agricultural Science · doi:10.5539/jas.v14n4p51
Atiyea, Q. M., Younus, R. W., Abdulkareem, H. S., & Hamad, A. M. (2022) · Bionatura · doi:10.21931/rb/2022.07.04.57
Wie wirksam sind Probiotika bei Reizdarm, CED und C.-difficile-Infektionen?
Toader, J., & Erhardt, A. (2023) · Gastro-News · doi:10.1007/s15036-023-3240-0
Hotfiel, K., Rist, M., & Raithel, M. (2023) · Die Gastroenterologie · doi:10.1007/s11377-023-00703-5
Dosa Postbiotic Food Preparations
Ambikapathy, V., Panneerselvam, A., Babu, S., Anbukumaran, A., Rani, A. S. S., Jagajothi, C., Kanmani, A., Rathna, D., & Prakash, P. (2023) · Methods and protocols in food science · doi:10.1007/978-1-0716-3421-9_55
Evaluación de la eficacia de los probióticos como tratamiento en el síndrome del intestino irritable
Ruiz-Sánchez, C., Escudero‐López, B., & Fernández‐Pachón, M. (2023) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2023.11.003
Ghoul, M. (2024) · Wiley eBooks · doi:10.1002/9781394312337.refs2
The Various Healthcare Applications of the Genus Lactobacillus
Narasimha, S. V., Zackria, R., Chadha, R., Gheriani, A. G., Johnson, L., Pattison, R., Kim, A., Chen, G., Ryan, J., & Shih, D. Q. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.115299
Yeni Nesil Fonksiyonel Bileşenler Olarak Postbiyotikler ve Biyoaktif Özellikleri
ÖZBAY, M., & ERSAN, L. Y. (2024) · Uludağ Üniversitesi Ziraat Fakültesi dergisi/Bursa uludağ üniversitesi ziraat fakültesi dergisi · doi:10.20479/bursauludagziraat.1485713
Mal, M. M., Arshad, F., Iftikhar, S., Tummala, N., Waqas, S. A., Kamal, U. H., Noor, R., Afridi, M. K., & Ali, A. (2024) · medRxiv · doi:10.1101/2024.11.29.24318034
Khan, M., Hasnain, H., Saad, M., Ashraf, M., `, S. S., Zaidi, S. M. Z., Naveed, R. M., Albanna, J., & Hanafi, Y. (2024) · Insights-Journal of Health and Rehabilitation · doi:10.71000/dtzf2h67
Kamiya, T. (2024) · Springer eBooks · doi:10.1007/978-981-97-8410-3_16
Precision medicine approaches to personalized probiotic therapy
Dinda, A., Banik, S., Kirtania, P., & Bhowmik, P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27594-4.00015-2
Ettinger, G. (2014) · Scholarship@Western (Western University)
Luo, M., Liu, Q., Xiao, L., & Xiong, L.-S. (2022) · Figshare · doi:10.6084/m9.figshare.19778232
Study of Alfalfa and Flaxseed Gums as Co-structurants in Probiotic Cryogel Scaffolds
Hellebois, T. (2023) · theses.fr (ABES) · doi:10.70675/7fc5548fz9c8fz4f0cza206z7f499edd9246
Halle-Smith, J. M., Fung, K. S. W., Efstathiou, E., Tovey, N., Stockton, J., Iqbal, T. H., Moss, P. A. H., Beggs, A. D., & Roberts, K. J. (2026) · Gut Science · doi:10.1136/gutsci-2026-000023
Withrow, N. A., Hsueh, E. E., Wolever, T., Jenkins, A. L., Campbell, J. C., Zurbau, A., McMahon, R., & Valentine, C. J. (2026) · Current Developments in Nutrition · doi:10.1016/j.cdnut.2026.109393
Probiotics: Advantages and Disadvantages in Veterinary Medicine
Hosseini, R. M., & Hajimohammadi, A. (2026) · Majallah-i taḥqīqāt-i dāmpizishkī-i īrān · doi:10.32598/ijvm.20.3.1005730
Cárdenas, J. P., Vidal‐Veuthey, B., Meza, K., Almonacid, D. E., & Gutkevich, A. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1744409
Fernandez, W. D., Vargas, V. P. S., Padilla-Zambrano, H., Cerino-Peñaloza, M. S., Saldaña-Ruiz, M. A., & Leggett, C. L. (2026) · Revista de Gastroenterología del Perú · doi:10.47892/rgp.2026.462.2230
Petitfils, C., & Cénac, N. (2025) · Dunod eBooks · doi:10.3917/dunod.poisb.2025.01.0910
Obukhova, O. A., & Kurmukov, I. A. (2026) · Clinical nutrition and metabolism · doi:10.17816/clinutr717075
Sallem, O. K. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1921349
Metadata
- Authors
- Guglielmetti, S., Mora, D., Gschwender, M., & Popp, K.
- Affiliations
- University of Milan (IT)
- Corresponding author
- Guglielmetti, S.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2011-03-21
- Volume
- 33
- Issue
- 10
- Pages
- 1123-1132
- ISSN
- 0269-2813 (ISSN-L)
- OpenAlex
- W2142855591
- Semantic Scholar
- e905099c40db3ed06be733b4cdc354afe771111b
- Cited by
- 287
- References
- 30
- Citations by year
- 2026: 12 · 2025: 8 · 2024: 33 · 2023: 24 · 2022: 24 · 2021: 15 · 2020: 17 · 2019: 15 · 2018: 25 · 2017: 17 · 2016: 12 · 2015: 15 · 2014: 27 · 2013: 21 · 2012: 13
- FWCI
- 22.92
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Alimentary Pharmacology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Trinity's Access to Research Output (TARA) (Trinity College Dublin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- irritable bowel syndrome, probiotics, quality of life, gut microbiota, intestinal barrier, IBS symptom severity, responder rate, tolerability
- MeSH terms
- Adult, Bifidobacterium, Double-Blind Method, Female, Humans, Intestines, Male, Middle Aged, Prospective Studies, Quality of Life, Treatment Outcome, Probiotics, Irritable Bowel Syndrome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
